News Snapshot:
FRANKFURT, Feb 10 (Reuters) - Astrazeneca said global interest in government purchase agreements for its COVID-19 vaccine was driven by strong demand in Latin America, the Middle East and Asia, even as aggregate global demand this year will fall. Speaking on a media call after the release of the company's fourth-quarter results, CEO Pascal Soriot said the shot, branded Vaxzevria, is receiving a "fantastic welcome" in those regions. The drugmaker earlier flagged a likely fall in COVID-19-related product sales this year, as an expected decline in vaccine revenue is to be partially offset by growth in sales of its antibody...
